|Articles|May 15, 2004
Proper patient selection improves results with PRL
Optical complications were substantial glare in about 20% of patients, halos in 30%, and problems with night driving in 20%.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Related Articles
- The European Commission grants marketing authorization for EYLUXVI
September 23rd 2025
- Luxa Biotechnology announces clinical trial results for treatment of AMD
September 22nd 2025
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Idebenone accepted by FDA for priority review for Leber Hereditary Optic Neuropathy
2
Luxa Biotechnology announces clinical trial results for treatment of AMD
3
The European Commission grants marketing authorization for EYLUXVI
4
FDA approves abbreviated new drug application from Amneal Pharmaceuticals for bimatoprost ophthalmic solution 0.01%
5